Sexual Rehabilitation: The Role of the Radiation Oncology Nurse

Article

Combined pelvic radiation therapy and intrauterine brachytherapy are frequently administered for locally advanced cervical and vaginal cancer. These therapies result in sexual dysfunction, namely vaginal shortening and decreased lubrication induced by fibrosis, stenosis, and mucosal atrophy.1-3 Vaginal dilator use is recommended to counter these untoward effects, yet many women fail to use this intervention. It is often perceived as intrusive, embarrassing, and foreign to usual measures of self-care. Researchers in the Netherlands undertook a prospective, longitudinal pilot study whereby four oncology nurses were trained to conduct an educational intervention with gynecologic patients undergoing pelvic radiation therapy and brachytherapy.4 The nurses received education from a number of interdisciplinary colleagues (i.e., sex therapists, psychologists, radiation, and gynecologic oncologists) and this education was delivered via lecture, role play, and group discussion. A treatment manual was developed for the nurses and they received monthly, 2-hour group supervision from the psychologists/sexual therapists during the duration of the study. Additionally, an educational booklet was developed for patients specific to sexual compromise associated with treatment. Outcome measures included frequency of dilator use, sexual functioning, and sexual, psychological, and relational distress measured at baseline, 1, 6, and 12 months post-therapy. Of those who completed the longitudinal assessment, sexual function improved between 1 and 6 months with further improvement evidenced at 1 year following treatment. Nurse-led sexual rehabilitation interventions which include instruction on dilator use, discussion of sexual issues, anxieties and coping responses during recovery, proved advantageous to patients participating in this pilot study. This research offers testimony to the efficacy of nurse-driven interventions to manage the treatment-specific sequelae associated with radiation therapy. Should these interventions be integrated into standardized care plans for women with gynecologic malignancies receiving radiation therapy? The answer is not yes, but how. References

  • Jensen PT, Froeding LP. Pelvic radiotherapy and sexual functioning in women. Transl Androl Urol. 2015 Apr; 4(2): 186–205.
  • Le Borgne G, Mercier M, Woronoff AS, et al. Quality of life in long-term cervical cancer survivors: a population-based study. Gynecol Oncol. 2013 Apr;129(1):222-8.
  • Brand A, Bull CA, Cakir B. Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):288-93.
  • Bakker RM, Mens JW, de Groot HE, et al. A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer. Support Care Cancer. 2017 Mar;25(3):729-737.

 

Recent Videos
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Related Content